Bank of America Lowers Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $7.00

Werewolf Therapeutics (NASDAQ:HOWL) had its target price decreased by stock analysts at Bank of America from $8.00 to $7.00 in a report released on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Several other research analysts also recently issued reports on HOWL. Weiss Ratings restated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Citigroup reiterated a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Zacks Research upgraded Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. Finally, JMP Securities reduced their price objective on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.75.

Werewolf Therapeutics Stock Up 2.9%

NASDAQ:HOWL traded up $0.03 on Tuesday, hitting $0.95. 249,879 shares of the company’s stock traded hands, compared to its average volume of 502,032. The firm has a 50-day moving average price of $1.57 and a 200-day moving average price of $1.34. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a 1 year low of $0.60 and a 1 year high of $2.38. The company has a market cap of $45.92 million, a PE ratio of -0.58 and a beta of 0.73.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.03. Equities analysts anticipate that Werewolf Therapeutics will post -1.56 EPS for the current fiscal year.

Insider Buying and Selling

In other news, major shareholder Ansbert Gadicke sold 140,488 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $1.22, for a total transaction of $171,395.36. Following the sale, the insider owned 6,007,122 shares in the company, valued at $7,328,688.84. This represents a 2.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Bioventures 2014 L.P. Mpm sold 140,488 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $1.22, for a total value of $171,395.36. Following the completion of the sale, the insider directly owned 6,007,122 shares of the company’s stock, valued at approximately $7,328,688.84. The trade was a 2.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,268,242 shares of company stock valued at $4,162,838. Corporate insiders own 23.60% of the company’s stock.

Institutional Trading of Werewolf Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Susquehanna International Group LLP increased its position in Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after buying an additional 13,439 shares during the period. MPM Bioimpact LLC boosted its holdings in Werewolf Therapeutics by 0.9% in the 1st quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock valued at $2,341,000 after purchasing an additional 20,799 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Werewolf Therapeutics by 33.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares in the last quarter. MPM Asset Management LLC increased its holdings in shares of Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock worth $4,189,000 after purchasing an additional 25,688 shares during the period. Finally, Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $28,000. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.